Roche dominates 2019’s big patent expirations Vantage
Of the five biggest products set to lose exclusivity in the US this year, the Swiss pharma giant owns three of them: Avastin, Herceptin and Tarceva. Hourglass.
Roche dominates 2019’s big patent expirations Vantage
Of the five biggest products set to lose exclusivity in the US this year, the Swiss pharma giant owns three of them: Avastin, Herceptin and Tarceva. Hourglass.